Cogstate Investor Presentation
Released
Released
Announcement PDF
| Page 1
ASX Announcement
25 November 2025
Cogstate Investor Presentation
All figures in US$, unless stated
Cogstate Limited (ASX: CGS) has released the attached investor presentation, which will be presented to investors
at the Barrenjoey Emerging Growth Conference in Sydney today.
Highlights:
• Market Growth and Opportunities
Cogstate estimates its niche CNS clinical trial solutions segment will grow from $600–$700 million today to
$1.0–$1.3 billion by 2030, representing a projected CAGR of 10%–15% over the next five years. The
broader eCOA market is anticipated to grow at 15% CAGR, supported by advances such as decentralised
trial methods and digital endpoint assessments.
• Expansion into New Therapeutic Areas and Global Reach
Cogstate continues to expand into new therapeutic areas, establishing leadership in central rating and
pursuing global expansion through strategic account growth and innovation in cognitive testing. The
company is also deepening consultative offerings for newer indications, strengthening its partnership
ecosystem.
• AI Integration and Digital Assessment Expansion
Cogstate’s platform now enables AI-assisted feedback through digital avatar support for rater training, and
automated review of rater assessments for higher data quality in clinical trials. Deep integrations with
strategic partners will maximise opportunities for AI-assisted solutions and real-time data insights for CNS
trials.
• Medidata Strategic Partnership
In October 2024, Cogstate announced its strategic partnership with Medidata, a leading provider of clinical
trial digital solutions. This collaboration enables deeply integrated electronic clinical outcome assessment
(eCOA) and innovative data quality solutions powered by AI and advanced analytics.
• Market Conditions
The demand for Cogstate services continues to grow, reflecting both growth in the market for R&D in
central nervous systems diseases as well as growth in market share by Cogstate. Each of the last four
quarters (from 2Q25 to 1Q26) has set a new record for the number of sales opportunities identified by
Cogstate, with those opportunities in the September quarter (1Q26) 72% higher than 1Q25. The growth in
sales opportunities identified reflects an expansion of both the Cogstate customer base and entry into new
indications. Cogstate management continues to carefully monitor win-rate from the associated increase in
proposals volume and is assessing the full impact of new channel partnerships, with further updates to be
provided throughout the course of the year.
This announcement was authorised for release by Cogstate Ltd CEO, Brad O’Connor.
For further information contact: investor@cogstate.com
| Page 2
About Cogstate
Cogstate Ltd (ASX: CGS) is a neuroscience technology company optimising brain health assessments to advance
the development of new medicines and to enable earlier clinical insights in healthcare. Cogstate technologies
provide rapid, reliable and highly sensitive computerised cognitive tests across a growing list of domains and
support partners in the delivery of electronic clinical outcome assessment (eCOA) solutions to replace costly and
error-prone paper assessments with real-time data capture. The company’s clinical trials solutions include quality
assurance services for study endpoints that combine innovative operational approaches, advanced analytics, and
scientific consulting. For over 20 years, Cogstate has proudly supported the leading-edge research needs of
biopharmaceutical companies and academic institutions, and the clinical care needs of physicians and patients
around the world. In the Healthcare market, Cogstate seeks to provide primary care physicians and consumers with
brief, accurate and scientifically validated digital measures of cognition, with a focus on easy to use, self-
administered tests that inform patients and save physician time. For more information, please visit
www.cogstate.com.
Important Notices
Past performance
Past performance is given for illustrative purposes only and should not be relied upon as (and is not) an indication
of Cogstate's views on its future financial performance or condition. Past performance of Cogstate cannot be relied
upon as an indicator of (and provides no guidance as to) the future performance of Cogstate. Nothing contained in
this announcement, nor any information made available to you is, or shall be relied upon as, a promise,
representation, warranty, or guarantee, whether as to the past, present or future.
Future performance and forward-looking statements
This announcement contains certain “forward-looking statements.” The words “expect,” “anticipate”, “estimate”,
“intend”, “believe”, “guidance”, “should”, “could”, “may”, “will”, “predict”, “plan” and other similar expressions are
intended to identify forward-looking statements. Indications of, and guidance on, future earnings and financial
position and performance are also forward-looking statements. Forward-looking statements, opinions and
estimates provided in this announcement are based on assumptions and contingencies that are subject to change
without notice and involve known and unknown risks and uncertainties and other factors that are beyond the
control of Cogstate, its directors and management. Forward-looking statements are provided as a general guide
only and should not be relied upon as an indication or guarantee of future performance.
Actual results, performance or achievements may differ materially from those expressed or implied in such
statements and any projections and assumptions on which these statements are based. These statements may
assume the success of Cogstate's business strategies, including the fact that the results of any of those strategies
will be realised in the period for which the forward-looking statement may have been prepared or otherwise. For
example, Cogstate's performance in any one financial period is sensitive to whether or not contracts are signed in
that period, or a subsequent period, and the rate of enrolment in trials of its customers, which are influenced by
factors that are outside of Cogstate's control.
Readers are cautioned not to place undue reliance on forward-looking statements and except as required by law or
regulations, none of Cogstate, its representatives or advisers, assumes any obligation to update these forward-
looking statements. No representation or warranty, express or implied, is made as to the accuracy, likelihood of
achievement or reasonableness of any forecasts, prospects, returns or statements in relation to future matters
contained in this announcement. The forward-looking statements are based on information available to Cogstate as
at the date of this announcement. Except as required by law or regulation (including the ASX Listing Rules), none
of Cogstate, its representatives or advisers undertakes any obligation to provide any additional or updated
information, whether as a result of a change in expectations or assumptions, new information, future events or
results or otherwise. Indications of, and guidance or outlook on, future earnings or financial position or performance
are also forward-looking statements.
High-tech, High-touch CNS Endpoint
Darren Watson
CHIEF FINANCIAL OFFICER
Rebecca Wilson
INVESTOR RELATIONS
Solutions for Trusted Signals
Disclaimer
This presentation has been prepared by Cogstate Limited (‘Cogstate’). The information in this presentation is of a general nature and does not purport to be
complete, nor does it contain all the information which would be required in a prospectus prepared in accordance with the requirements of the Corporations Act.
This presentation may contain statements, opinions, projections, forecasts and other material (forward looking statements), based on various assumptions. Those
assumptions may or may not prove to be correct. None of Cogstate, its respective officers, employees, agents, advisers or any other person named in this
presentation makes any representation as to the accuracy or likelihood of fulfilment of any forward-looking statements or any of the assumptions upon which they
are based.
The information contained in this presentation does not take into account the investment objectives, financial situation or particular needs of any recipient and is
not financial product advice. Before making an investment decision, recipients of this presentation should consider their own needs and situation and, if
necessary, seek independent, professional advice.
To the extent permitted by law, Cogstate and its respective officers, employees, agents and advisers give no warranty, representation or guarantee as to the
accuracy, completeness or reliability of the information contained in this presentation. Further, none of Cogstate and its respective officers, employees, agents
and advisers accept, to the extent permitted by law, responsibility for any loss, claim, damages, costs or expenses arising out of, or in connection with, the
information contained in this presentation. Any recipient of this presentation should independently satisfy themselves as to the accuracy of all information
contained herein.
3
We partner with drug developers to
power complex neuroscience studies
Our applied technology solutions include:
• fit-for-purpose data quality programs,
• advanced analytics, and
• digital cognitive tests
to identify clear signals for confident decision making
The Power To Cut Through The Noise
Cogstate
ensures
The right assessments
are used
The clinicians are trained
and monitored to deliver
assessments correctly,
regardless of geography
or language
The electronic data
capture systems are
optimized to reduce error
Usability is data quality
Why Cogstate?
Premier CNS endpoint partner
Cogstate uniquely specialises in the science
and service of CNS measurement, delivering fit-
for-purpose solutions across endpoint design,
deployment, and validation that reduce trial risk
and ensure the confidence that drug developers
need.
Track record of clinical trial success
Over the last two decades, Cogstate has
contributed to 9 regulatory approvals across
depression, schizophrenia, bipolar disorder, and
Alzheimer's disease, and is the only company to
successfully deliver central rating across pivotal
Alzheimer’s studies.
25 years of CNS testing innovation
Pioneering digital cognitive testing in CNS trials,
Cogstate has built decades of proprietary
assessment IP, validated through peer-reviewed
research and real-world deployment,
administered +2M times and trusted by leading
pharma/biotech companies.
Technology-enhanced endpoint quality
Cogstate is applying the same digital
transformation across its endpoint services,
offering an integrated platform that includes
technological innovations in data quality review,
programmatic rater training, multilingual central
monitoring, and predictive analytics.
Global CNS expertise
Our internal team of CNS scientists and
clinicians, combined with a multi-national
network of 300+ credentialed neuropsychiatric
professionals across 50+ languages, provides
specialised, accessible expertise.
Best-in-class partnerships
Cogstate’s premier capabilities are enhanced
through its strategic partnership with Medidata
and its industry-leading eCOA platform to
provide a seamless experience for
pharma/biotech sponsors that reshapes clinical
trials through faster clinical trial starts and
validated results.
Estimate ~10-15% CAGR for this sub-segment
over the next 5 years, given:
Estimates ~ 8-10% of CNS trials TAM is
endpoint licensing and data-quality solutions
1
2
We estimate our niche
segment will grow
from ~$600-700
million today to ~$1.0-
1.3 billion by 2030
e-COA market ~15% CAGR
Broader neurology CRO market ~6-8% CAGR
Advances like decentralized trial methods,
remote/central raters, and digital
assessments support higher growth
• Expanded Offerings
• Product Innovation
• Channel Partners &
Integrations
6
Indication Expansion
• Scientific expertise in mood disorders, with the
appointment of Dr. Luka Lucić
• 1Q26: executed $6.9m of sales contracts in psychiatry /
mood trials, compared to $3.2m all FY25
Greater Share of Contract Value
• Continued growth in Cogstate network, now over 360
consulting clinicians supporting 51 languages
• Enables Cogstate to offer data review as well as
centralised assessment via telehealth visits
• Centralised assessment, using consultants, increases
Cogstate revenue (greater share of trial budget)
• Expanded Offerings
• Product Innovation
• Channel Partners &
Integrations
7
• Expanded Offerings
• Product Innovation
• Channel Partners &
Integrations
8
Number of New
Opportunities
Number of New
Contracts
Identified sales opportunities are growing.
Closely monitoring win rates
Alzheimer's Disease
56%
Rare Disease
19%
Narcolepsy
6%
Depression
5%
Parkinson's Disease
4%
Huntingdon's Disease
2%
Schizophrenia
2%
FY25 Sales Contracts by Value
Growth AND Diversification:
1Q26 sales contracts $21.4m, up 88% pcp
Alzheimer's Disease
33%
Rare Disease
19%
Depression
17%
Schizophrenia
14%
Narcolepsy
11%
Tremor
3%
Parkinson's Disease
2%
1Q26 Sales Contracts by Value
Background Information | ASX:CGS
Market Cap ~A$450m
Shares on issue 171.6m
Options on issue (avg ex. price $1.915) 2.7m
Performance Rights on issue 7.5m
Major shareholders:
• Dolby family (Dolby Labs, San Fran) 17%
• Myer family (Chairman) 14%
• Aust Ethical Investment (Sydney) 9%
• Other Board & Management 4%
• Top 20 shareholders ~80%
54%
58%
51%
56%
61%
18%
24%
7%
16%
26%
0
10
20
30
40
50
60
FY21 FY22 FY23 FY24 FY25
US$
Million
Revenue & Profitability,
by Financial Year
Revenue Gross Profit Profit Before Tax
All figures in US$, unless noted
FY25 Operational and Financial Highlights
Revenue Growth Total revenue of $53.1 million, up 22%. Clinical Trials revenue $50.6 million, up 28%.
Capital Efficiency $11.5 million operating cash flow. Cash balance $35.6 million (after $4.8 million share buy-back).
Clinical Trials
Momentum
FY25 Clinical Trials sales contracts $41.3 million, up 53%.
1Q26 $21.4 million executed, up 88% pcp
Margin Expansion
Gross margin of 61%, EBITDA margin of 30%, and EBIT margin of 25%.
$9.7m increase in Revenue resulted in $6.8m increase in Profit Before Tax
Record Profit Profit before tax $13.9 million, up 96%. NPAT $10.1 million, up 86%.
Maiden Dividend Fully franked dividend of A$0.02 paid Sep-2025. Pay-out ration 20%-50% NPAT annually.
All figures in US$, unless noted
Share your feedback
Discover